Suchergebnisse - "Guo, Xi-Ling"

PubPharm (18)

1

Environmental Impact Assessment for the Use of an Orally Aerosolized Adenovirus Type-5 Vector-Based COVID-19 Vaccine in Randomized Clinical Trials

enthalten in: The Journal of infectious diseases | 2023

von Xia, X. | Tan, Z. | Wan, P. | +11

2

Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac : a multicentre, open-label, phase 4, randomised trial

enthalten in: The Lancet. Respiratory medicine | 2023

von Tang, R. | Zheng, H. | Wang, B. | +24

3

Immunogenicity and safety of heterologous immunisation with Ad5-nCOV in healthy adults aged 60 years and older primed with an inactivated SARS-CoV-2 vaccine (CoronaVac) : a phase 4, randomised, observer-blind, non-inferiority trial

enthalten in: The Lancet regional health. Western Pacific | 2023

von Jin, P. | Guo, X. | Gou, J. | +20

4

Immunogenicity consistency and safety with different production scales of recombinant adenovirus type-5 vectored COVID-19 vaccine in healthy adults : a randomized, double-blinded, immunobridging trial

enthalten in: Expert review of vaccines | 2023

von Wu, Y. | Wei, M. | Wang, R. | +11

5

Head-to-head comparisons of the neutralizing antibody against SARS-CoV-2 variants elicited by four priming-boosting regimens

enthalten in: Emerging microbes & infections | 2022

von Jiang, H. | Guo, X. | Jin, P. | +3

6

Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults : a randomised, open-label, single-centre trial

enthalten in: The Lancet. Respiratory medicine | 2022

von Li, J. | Wu, S. | Guo, X. | +42

7

A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2

enthalten in: bioRxiv.org | 2021

von Zhang, L. | Cao, L. | Gao, X. | +20

8

A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2

enthalten in: National science review | 2021

von Zhang, L. | Cao, L. | Gao, X. | +24

9

Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older : two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials

enthalten in: Signal transduction and targeted therapy | 2021

von Meng, F. | Gao, F. | Jia, S. | +16

10

Outbreak of Vaccinia Virus Infection from Occupational Exposure, China, 2017

enthalten in: Emerging infectious diseases | 2019

von Lu, B. | Cui, L. | Gu, M. | +8